1 Autoantibodies against nephrin elucidate a novel autoimmune phenomenon in proteinuric

- 2 kidney disease
- 3

4 <u>Authors</u>

- 5 Andrew J.B. Watts^{1,2}*, Keith H. Keller¹*, Gabriel Lerner^{3,4}, Ivy Rosales⁵, A. Bernard Collins⁵,
- 6 Miroslav Sekulic^{1,6}, Sushrut S. Waikar^{2,4}, Anil Chandraker², Leonardo V. Riella², Mariam P.
- 7 Alexander⁷, Jonathan P. Troost⁸, Junbo Chen³, Damian Fermin⁹, Jennifer Lai Yee⁹, Matthew
- 8 Sampson^{10,11}, Laurence H. Beck, Jr.⁴, Joel M. Henderson³, Anna Greka^{2,11}, Helmut G. Rennke¹,
- 9 and Astrid Weins^{$1,2,\dagger$}
- 10

¹Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School,
Boston, MA

- ²Renal Division, Department of Medicine, Brigham and Women's Hospital, and Harvard
 Medical School, Boston, MA
- ³Department of Pathology, Boston Medical Center and Boston University, Boston, MA
- ⁴Section of Nephrology, Department of Medicine, Boston Medical Center and Boston
 University, Boston, MA
- 18 ⁵Department of Pathology, Massachusetts General Hospital, and Harvard Medical School,
- 19 Boston, MA
- ⁶Department of Pathology and Cell Biology, Columbia University College of Physicians and
- 21 Surgeons
- ⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
- ⁸Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI

	24	⁹ Division of	Medicine,	Department	of Pediatrics,	University	of Michigan	School of Medicine
--	----	--------------------------	-----------	------------	----------------	------------	-------------	--------------------

- 25 Ann Arbor, MI
- 26 ¹⁰Department of Medicine/Pediatric Nephrology, Boston Children's Hospital, and Harvard
- 27 Medical School, Boston, MA
- 28 ¹¹Broad Institute of MIT and Harvard, Cambridge, MA
- 29
- 30 *These authors contributed equally to this study.
- 31
- 32 [†]Corresponding author:
- 33
- 34 Astrid Weins, M.D., Ph.D.
- 35 Associate Pathologist, Department of Pathology, Brigham and Women's Hospital
- 36 Assistant Professor of Pathology, Harvard Medical School,
- 37 Cotran-3, Room AL380.B
- 38 75 Francis Street
- 39 Boston, MA 02115
- 40 Phone: 617-732-7671
- 41 <u>aweins@bwh.harvard.edu</u>

- 43
- 44
- 45
- 46

47

48

49 Abstract

50 Dysfunction of podocytes, cells critical for glomerular filtration, underlies proteinuria and kidney 51 failure. Genetic forms of proteinuric kidney disease can be caused by mutations in several 52 podocyte genes, including nephrin, a critical component of the kidney filter. In contrast, the 53 etiology of acquired acute-onset nephrotic syndrome has remained elusive. Here we identify 54 autoantibodies against nephrin in serum and glomeruli of a subset of adults and children with 55 non-congenital acute nephrotic syndrome. Our findings align with published experimental 56 animal studies and elucidate a novel autoimmune phenomenon in proteinuric kidney disease 57 interfering with glomerular filter integrity.

58

59 Introduction

60 Diffuse podocytopathy with minimal changes (Minimal Change Nephrotic Syndrome, MCNS) is an important and common pathologic diagnosis in adults and children with nephrotic syndrome 61 62 (NS). It is characterized by minimal changes by light microscopy, but extensive injury to 63 glomerular podocytes with diffuse foot process effacement (FPE) and loss of slit diaphragms 64 (SD) by electron microscopy (EM) in the absence of electron dense deposits¹. The consequence 65 of these alterations is massive proteinuria secondary to failure of the glomerular filtration barrier 66 (GFB), whose integrity is critically dependent on the specialized junctional SD protein complex 67 linking the interdigitating podocyte foot processes.

Nephrin is an essential component of the $SD^{2,3}$, as illustrated by genetic mutations in nephrin, 69 that cause complete lack of cell surface localization, underlying Congenital Nephrotic Syndrome 70 of the Finnish Type (CNF)^{4,5}. In contrast to congenital NS with an established genetic basis, the 71 72 cause of non-congenital NS in both children and adults remains largely unknown. There is strong 73 evidence supporting immune dysregulation with a potential causative circulating factor, however its identity has remained elusive^{6,7}. Glucocorticoids are effective at inducing remission, however 74 75 relapse, steroid dependence and intolerance are common, often requiring alternative immunosuppressive agents⁸. In those patients with steroid dependent NS who progress to end 76 stage kidney disease (ESKD) and require kidney transplantation, the disease can promptly recur 77 78 in the allograft¹.

79

The recent discovery that anti-CD20 B-cell targeted therapies are effective in children with frequently relapsing or steroid-dependent NS⁹⁻¹¹ and in adults¹² suggests a potential autoantibody-mediated etiology. However, this possibility is hard to reconcile with the traditional view of MCNS lacking IgG deposition on renal biopsy¹³. Whilst diffuse podocyteassociated IgG is described in MCD, it is minimal compared to that seen in membranous nephropathy (MN), and in the absence of deposits by EM is generally attributed to non-specific protein resorption of little significance¹⁴.

87

Antibodies targeting this essential SD component nephrin have been shown to cause massive proteinuria when administered in animal models¹⁵⁻¹⁷ and when they arise as alloantibodies following kidney transplantation in children with CNF and complete nephrin deficiency¹⁸. In both animal models^{15,16} and cultured podocytes^{7,19}, anti-nephrin antibodies cause a redistribution

92 of nephrin that is identical to that observed in renal biopsies of patients with NS^{20,21}. This 93 redistribution of nephrin away from the SD has been proposed as a mechanism to explain the 94 proteinuria in these patients; however, the cause of this redistribution remains unknown.

95

96 Differing from classic immune complex deposition diseases such as membranous nephropathy, 97 the phenomenon of functional autoantibody-mediated disruption of a junctional adhesion 98 complex is well described for the blistering skin condition pemphigus²². In this disease, 99 autoantibodies directly bind desmogleins (dsg), a critical constituent of the desmosomal cell 100 adhesion complex, analogous to nephrin in the SD complex, and cause redistribution of dsg away 101 from the cell surface with consequent loss of desmosomal integrity and ultimately cell-cell 102 interactions²².

103

104 Taken together these observations led us to hypothesize that autoantibodies against nephrin may105 underlie non-congenital MCNS by affecting the integrity of the SD complex.

106

107 <u>Results</u>

To first determine whether circulating autoantibodies against nephrin are detectable in the serum of patients with biopsy proven MCD and no known genetic basis (lacking known pathogenic variants in established Mendelian NS genes), we evaluated serum obtained from the Nephrotic Syndrome Study Network (NEPTUNE) longitudinal cohort study²³ consisting of 41 (66%) children and 21 (34%) adults (Table S1). We developed an indirect enzyme-linked immunosorbent assay (ELISA) using a recombinant, affinity purified extracellular domain of human nephrin (hNephrin_{G1059}) (Fig. S1) and established a threshold for anti-nephrin antibody

(ab) positivity, based on the maximum titer in a healthy control population (n=30) (Fig. 1a). Evaluation of the earliest serum sample obtained during active disease (urine protein to creatinine ratio, UPCR > 3g/g) revealed that 18 (29%) of 62 patients, with an equal number of adults and children, were positive for autoantibodies against nephrin (Fig. 1a). Control sera from 53 (98%) of 54 patients who tested positive for anti-hPLA₂R antibodies, by clinically validated ELISA and indirect immunofluorescence test (IIFT) assays, were negative for anti-nephrin ab (Fig. 1a).

122

The patients' clinical characteristics (Table S2) and the median time from enrollment to complete remission (CR) were similar between the anti-nephrin ab positive and negative groups (4.4 months vs 5.4 months respectively; p=0.7288) (Fig. S2). However, the relapse-free period was shorter for the anti-nephrin ab positive group compared with the ab negative group, although this finding did not reach conventional levels of statistical significance (median time to relapse 6.0 months vs 21.57 months respectively; p=0.0945) (Fig. S2).

129

A subsequent serum sample was available during either complete (UPCR < 0.3 g/g) or partial remission (>50% reduction in proteinuria) from 12 of the 18 anti-nephrin ab positive patients, in whom we observed a complete absence or a significant reduction of nephrin autoantibodies respectively (Fig. 1b, Figs. S3, S4). In keeping with the ELISA results, only serum obtained during active disease or partial remission immunoprecipitated nephrin from healthy donor kidney derived human glomerular extract (HGE), whereas serum obtained during complete remission did not (Fig. 1c).

To further investigate a potential pathogenic role of these nephrin autoantibodies, we next sought to establish whether they are present within kidneys of patients with MCD. One limitation of the NEPTUNE cohort is that biopsy material from these patients was not available for further evaluation and so we turned to our own institution and collaborators for biopsy and serum samples.

143 For many years, we have observed a delicate punctate staining for IgG in a subset of patients 144 with MCD (MCD+) by routine immunofluorescence staining that is distinct from the background 145 (Fig. S5a). It is much more subtle when compared to the prominent IgG staining observed in MN (Fig. S5a), and while this feature has been previously described¹⁴, its significance has not been 146 147 fully established. We therefore hypothesized that this subtle IgG may represent autoantibodies 148 targeting nephrin. To limit the possibility of staining artifacts, we routinely use a directly conjugated FITC anti-huma IgG F(ab)₂ ab which we have independently validated with a distinct 149 150 unconjugated anti-human IgG ab, an anti-light chain ab and isotype specific anti-IgG abs that all 151 show an identical staining pattern (Fig. S6). Importantly, we observe a complete lack of 152 concurrent glomerular albumin staining, indicating that this feature is IgG selective and does not 153 reflect non-specific protein resorption (Fig. S6).

154

We utilized confocal microscopy to further evaluate this punctate IgG in renal biopsies that were received and processed by us over the last 3 years. We observed two predominant patterns of IgG distribution: GBM-associated fine punctate or curvilinear structures and more apically located punctate and vaguely vesicular clusters. These disparate staining patterns may reflect different stages of antibody binding and/or redistribution. In all the MCD+ biopsies evaluated, we observed specific co-localization of nephrin with the punctate IgG and not the background

161 (Fig 2a, Fig. S5b, Fig. S7) which was further corroborated in the control biopsies lacking this 162 punctate IgG (Fig. 2a, Fig. S5b). Antigen specificity was evidenced by a clear spatial association 163 of the IgG with the SD-associated nephrin but not with the podocyte foot process associated 164 synaptopodin by confocal microscopy (Fig. 2a,b, Fig. S5c) and by Super-Resolution Structured Illumination Microscopy (SR-SIM) which achieves an even higher spatial resolution²⁴ (Fig. 2c,d, 165 166 Fig. S8). Furthermore, in those biopsies exhibiting the granular redistribution of nephrin away from the SD, as previously described in MCD^{20,21}, the IgG did not co-localize with the three 167 168 intracellular podocyte specific proteins; synaptopodin (foot process associated), podocin (SD 169 associated) and WT1 (nuclear) (Fig. S9).

170

171 To confirm that MCD+ patients with punctate IgG on renal biopsy do indeed have circulating 172 autoantibodies against nephrin, we evaluated serum or plasma that was available specifically 173 during active disease for 9 of them. As expected, all 9 patients were serologically positive for 174 anti-nephrin antibodies by ELISA, in contrast to 12 control patients lacking punctate IgG on 175 renal biopsy, who were all serologically negative (Fig. 2e, Table S3). A follow-up serum or 176 plasma sample was available for 4 of the 9 MCD+ patients, which showed a significant reduction in antibody titer concordant with treatment response (Fig. 2f, Fig. S10). These findings were 177 178 corroborated by IP (Fig. S11), and for all the patients in this study who were serologically positive for circulating nephrin autoantibodies they did not cross react with PLA₂R (Fig. S12). 179

180

Finally, to highlight a potential role of pre-transplant nephrin autoantibodies in post-transplant
disease recurrence, which generally shows morphologic features indistinguishable from MCNS,
we identified a patient with childhood onset, steroid dependent MCNS and no underlying genetic

basis (as determined by clinical whole exome sequencing) who progressed to ESKD requiring
kidney transplantation. In keeping with a pathogenic role for anti-nephrin autoantibodies, the
patient developed massive proteinuria early post-transplant, that in contrast to CNF^{18,19} was
associated with high pre-transplant levels of nephrin autoantibodies (Fig. S13).

188

189 Discussion

190 Herein, we describe the discovery of circulating autoantibodies against the extracellular domain 191 of nephrin, the essential constituent of the podocyte SD, in a subset of patients with non-192 congenital acute nephrotic syndrome. These nephrin autoantibodies are specifically present in 193 MCNS kidney biopsies, forming distinct clusters. Our observations share striking parallels with 194 the autoimmune blistering skin condition pemphigus, in which circulating autoantibodies target the desmosomal cell adhesion molecules desmogleins $(dsg)^{22}$. In pemphigus, these 195 196 autoantibodies directly interfere with cell adhesion through redistribution, clustering and endocytosis of dsg that disrupts the integrity of the desmosome²². Previous reports of 197 198 experimental anti-nephrin antibody mediated disruption of nephrin homophilic interactions further support this potential mechanism in MCNS³. Furthermore, pemphigus exhibits a rapid 199 200 response to glucocorticoid treatment (within days to weeks) that cannot be explained by reduced 201 IgG synthesis alone and may be due to compensatory desmoglein synthesis in keratinocytes²⁵. 202 Similarly, most cases of MCNS respond rapidly to glucocorticoids (within weeks) which have also been shown to upregulate nephrin cell surface expression in cultured human podocytes²⁶. 203 204 Based on these findings, we speculate that the IgG co-localizing with nephrin in MCNS kidney 205 biopsies may represent in situ binding of nephrin autoantibodies. This binding may trigger the 206 redistribution of nephrin and result in SD failure with acute onset, massive proteinuria.

207

208 Recurrent acute nephrotic syndrome in the allograft, referred to as "recurrent FSGS" (rFSGS) in 209 patients with a history of acute nephrotic syndrome in the native kidney, is morphologically 210 indistinguishable from MCNS. Therefore, we also included a study in a transplant patient with an 211 initial diagnosis of MCD in the native kidney which then progressed to FSGS and eventually ESKD. This patient rapidly developed acute and high proteinuria post-transplant consistent with 212 213 rFSGS, which was not confirmed by a biopsy; however, the pre-transplant serum showed high 214 levels of anti-nephrin antibodies which decreased after aggressive and successful treatment with 215 rituximab and plasmapheresis; this patient went into sustained remission and retained the 216 transplant. We realize that without further corroboration in a larger rFSGS patient sample, no 217 definitive conclusions can be drawn. However, this case illustrates the need to advocate for a comprehensive analysis of anti-nephrin antibodies also in this group of patients with a much 218 219 more devastating prognosis.

220

In conclusion, our discovery adds new insights into the etiology of a disease that has been poorly understood for decades. Future studies will be needed to establish the prevalence of this new subset of anti-nephrin antibody positive NS and the prognostic benefit of anti-nephrin antibodies as a novel, minimally invasive biomarker. Nevertheless, our work provides a mechanistic rationale for consideration of B-cell targeted therapy in a subset of NS patients and allows us to molecularly define those patients who stand to benefit most from the development of new, targeted therapeutic strategies for anti-nephrin antibody positive NS.

228

230 Methods

231 Clinical samples (Kidney tissue and serum/plasma)

232 Renal biopsies were independently assessed by collaborating renal pathologists across four 233 institutions: Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH), 234 Boston Medical Center (BMC) and the Mayo Clinic. Serum/plasma was obtained from patients attending those institutions as either discarded samples originally collected for clinical analysis 235 236 (BWH/BMC/Mayo clinic) or archival samples from the Kidney Disease Biobank (courtesy of 237 Dr. Sushrut Waikar, Partners Healthcare, in accordance with Partners Healthcare IRB Approval 238 for patients attending BWH or MGH and were consented for serum/plasma collection at the time 239 of renal biopsy). Histological studies were performed on archival kidney tissue that was received 240 for routine clinical evaluation and included diffuse podocytopathies, other nephrotic conditions, 241 and non-neoplastic renal parenchyma from tumor nephrectomies. Medical record review, 242 histological and serological studies were approved by the respective Institutional Review Boards 243 (IRB) for those institutions. Similarly, sera were obtained from patients with biopsy proven 244 minimal change disease (MCD) from the Nephrotic Syndrome Study Network (NEPTUNE) longitudinal study²³ during active disease and where available, in remission. Healthy control 245 246 sera were randomly selected from Partners Healthcare Biobank, specifically excluding those 247 subjects with any renal or autoimmune disease. Sera from nephrotic patients were evaluated for 248 anti-hPLA₂R antibodies at the MGH Immunopathology laboratory using a commercial enzyme 249 linked immunosorbent assay (ELISA) and indirect immunofluorescence test (IIFT) 250 (Euroimmun). Samples were coded to preserve patient anonymity.

251

253 Whole genome sequencing of the NEPTUNE cohort

Whole genome sequencing with a goal median depth of 30x was performed using Illumina Hiseq. A standard pipeline, Gotcloud, was applied for sequence alignment and variant calling^{27,28}. The variant analysis focused on approximately 70 genes implicated in Mendelian NS. To screen pathogenic variants in the 70 previously implicated Mendelian NS genes, we employed a pipeline similar to one that has been previously reported²⁹. The pathogenicity variants were ultimately classified according to ACMG standards and guidelines³⁰.

260

261 Human glomerular extract

Human glomerular extract (HGE) was prepared as previously described by Beck *et al*³¹. Briefly, glomeruli were isolated from human kidneys deemed non-suitable for transplantation (that had been authorized for use in medical research) obtained from New England Donor Services, by graded sieving followed by isolation of glomerular proteins in RIPA buffer (Boston BioProducts). IgG was pre-cleared from tissue lysate by incubation with Protein G Plus agarose beads (Santa Cruz). Only kidneys with less than 20% global glomerulosclerosis, on routine wedge biopsy, were used for glomerular isolation.

269

270 Routine renal biopsy processing

After biopsy acquisition, renal cortex was immediately allocated for light (10% neutral-buffered formalin), immunofluorescence (Zeus transport media) and electron microscopy (Karnovsky's fixative) processing. For routine clinical immunofluorescence, 4 μ m cryosections were fixed in 95% ethanol for 10 minutes and incubated with FITC-conjugated polyclonal rabbit F(ab)₂ antihuman IgG antibody (Dako; F0315) diluted 1:20. FITC-conjugated sheep anti-human IgG1,

IgG2, IgG3, IgG4 (Binding Site; AF006, AF007, AF008, AF009, respectively) diluted 1:20 were
used for IgG subclass evaluation. Albumin was detected using FITC-conjugated polyclonal
rabbit anti-human albumin (Dako; F0117) diluted 1:30. Sections were mounted using Dako
fluorescence mounting medium (Dako; S3023) with a #1.5 coverslip. Immunofluorescence
images were acquired on an Olympus BX53 microscope with an Olympus DP72 camera at 150
ms exposure.

282

283 Confocal microscopy

284 For confocal microscopy, 4 µm cryosections of human kidney biopsies were fixed in 95% 285 ethanol for 10 minutes and subsequently blocked for one hour at room temperature (RT) with 286 phosphate buffer saline (PBS) supplemented with 0.2% fish gelatin, 2% bovine serum albumin 287 (BSA) and 2% fetal bovine serum (FBS). All antibodies were diluted in this blocking solution 288 and incubated for one hour at RT. Nephrin was detected using 1 µg/ml primary polyclonal sheep anti-human nephrin (R&D systems; AF4269) followed by a secondary AlexaFluorTM 568-289 290 conjugated donkey anti-sheep IgG (Invitrogen; A21099). Synaptopodin was detected using anti-291 synaptopodin (N-terminus) guinea pig polyclonal antiserum (Progen; GP94-N) diluted 1:1000 followed by a secondary AlexaFluorTM 568-conjugated goat anti-guinea pig IgG (Invitrogen; 292 A11075) antibody. Podocin and Wilms Tumor 1 (WT1) were detected using a primary 293 294 polyclonal rabbit anti-human podocin (Millipore Sigma; P0372) and a primary monoclonal 295 rabbit anti-human WT1 clone SC06-41 (Invitrogen; MA5-32215) diluted 1:500 and 1:300 respectively, followed by a secondary AlexaFluorTM 568-conjugated donkey anti-rabbit IgG 296 297 (Invitrogen; A10042). IgG immune deposits were detected using a primary monoclonal mouse 298 anti-human IgG antibody (Abcam; ab200699) diluted 1:750 followed by a secondary

AlexaFluorTM 488-conjugated donkey anti-mouse IgG (Invitrogen; A21202). All secondary
AlexaFluorTM-conjugated antibodies were diluted 1:500. Sections were mounted using
Vectashield anti-fade mounting medium (Vectashield, H-1000) with a #1.5 coverslip and images
were acquired on a Leica TCS SPE microscope.

303

304 Structured Illumination Microscopy (SIM)

305 Structured Illumination Microscopy (SIM) imaging was performed on 4 μ m fixed, frozen human 306 kidney biopsy sections processed according to the aforementioned protocol for confocal 307 microscopy. All images were collected using an OMX V4 Blaze (GE Healthcare) microscope 308 equipped with three watercooled PCO.edge sCMOS cameras, 488 nm, 568 nm laser lines, and 309 528/48 nm, 609/37 nm emission filters (Omega Optical). Images were acquired with a 60X/1.42310 Plan-Apochromat objective lens (Olympus) with a final pixel size of 80 nm. Z stacks of 4-8 µm, 311 were acquired with a 0.125 μ m z-spacing, and 15 raw images (three rotations with five phases 312 each) were acquired per plane. Spherical aberration was minimized for each sample using immersion oil matching²⁴. Super resolution images were computationally reconstructed from the 313 314 raw data sets with a channel-specific, measured optical transfer function, and a Wiener filter 315 constant of 0.001 using CUDA-accelerated 3D-SIM reconstruction code³². Axial and lateral 316 chromatic misregistration was determined using a single biological calculation slide, prepared 317 with human kidney tissue stained with a primary mouse anti-human IgG monoclonal antibody (Abcam; ab200699) followed by both secondary AlexaFluorTM 488-conjugated donkey anti-318 mouse IgG (Invitrogen; A21202) and AlexaFluorTM 568-conjugated goat anti-mouse IgG 319 320 (Invitrogen; A11031) antibodies on the same tissue cryosection. Experimental data sets were then registered using the imwarp function in MATLAB (MathWorks)³³. 321

322

323

324 Generation of recombinant human nephrin and phospholipase A₂ receptor (PLA₂R)

325 Separate plasmids encoding the extracellular subdomains of human nephrin (amino acids 1-326 1059), comprising the 8 Ig-like C2-type domains and a single fibronectin type III domain, and 327 human phospholipase A2 receptor (hPLA₂R), comprising the N-terminal ricin domain, 328 fibronectin type II domain and 8 C-type lectin domains (CTLD), both with C-terminal 329 polyhistidine (6XHIS) tags, were generated by standard cloning techniques. The correct 330 sequences were confirmed by whole plasmid sequencing (MGH DNA core). HEK293-F cells (Thermo Fisher) were transfected with 0.5 μ g plasmid per 10⁶ cells using 1.5 μ g PEI 331 332 (polyethylenimine). The plasmid and PEI were pre-incubated for 20 mins in Freestyle media 333 (Thermo Fisher) at one tenth the final volume and then added dropwise to the cells. After 3-5 334 days, provided the cell viability was >95%, the cell culture media was harvested by 335 centrifugation (300 xg for 10 mins). Imidazole was added to a final concentration of 10 mM and 336 the media was filter sterilized (0.2 μ m) on ice. Nickel NTA resin (Oiagen) was washed 3x with 337 10 mM Imidazole in PBS and then incubated with the filtered media overnight at 4°C on a roller 338 mixer (Thermo Fisher). The Nickel NTA resin was then washed 3x with 10 mM Imidazole in 339 PBS and the recombinant proteins were eluted with 300 mM Imidazole in PBS. The purity of the 340 eluted fractions was confirmed by SDS-PAGE with a 4-12% Bis-Tris gel (Invitrogen), pooled 341 together and concentrated to 1 ml using an Amnicon centrifugation filter with a 10K molecular weight cut off (Millipore). The resultant protein was run over a SephadexTM 300 column and 0.5 342 343 ml fractions were collected. The purity of the eluted fractions was confirmed by SDS-PAGE on a 344 4-12% Bis-Tris gel (Invitrogen) and the concentration determined by measuring absorbance at

345	280 nm using a Nanodrop spectrophotometer (Thermo Fisher). Immunoreactivity of the purified
346	nephrin was confirmed by Western blot analysis, under reducing conditions using a primary
347	sheep anti-human nephrin antibody (R&D) followed by a secondary HRP-conjugated donkey
348	anti-sheep IgG antibody (Jackson immunoresearch), and of the purified hPLA2R under non-
349	reducing conditions using serum from a patient with known anti-PLA ₂ R antibodies (determined
350	by commercial ELISA and IIFT (Euroimmun)) diluted 1:1000 and a secondary HRP-conjugated
351	donkey anti-human IgG antibody (Jackson Immunoresearch).
352	
353	Enzyme Linked Immunosorbent Assay (ELISA)
354	Please contact the corresponding author for information.
355	

356 Immunoprecipitation and Western Blot

357 Please contact the corresponding author for information.

358

359 Acknowledgements

360 We acknowledge Lin Shao (Yale University) for CUDA-accelerated 3D-SIM reconstruction 361 code, and Talley Lambert, Anna Payne-Jost and Jennifer Waters (Nikon Imaging Core, Harvard 362 Medical School) for assistance with SIM acquisition. We are grateful to Dr. Opeyemi Olabisi for 363 ApoL1 genotyping, and Drs. Emily Dulude, Durga Rao and Andrew Bentall for providing 364 supporting clinical data. We are thankful to Dr. Colin Garvie and Dr. Kasia Handing for 365 assistance with protein purification. We thank Terri Woo, Colleen Ford, Kristie Swett, Hui Chen 366 and Brant Douglas for expert technical assistance, and Dr. Andrew Lichtman, Dr. David Salant, 367 Dr. Moran Dvela, Dr. Juanchi Pablo, Dr. Silvana Bazua Valenti, Dr. Katherine Vernon, Dr.

368 Valeria Padovano and Morgan Thompson for enlightening discussions. We thank Dr. Camden 369 Bay from Harvard Catalyst for biostatistics consultation. A.J.B.W. was supported by T32 370 training fellowships T32HL007627 and T32DK007527. A.W. was supported by an Eleanor 371 Miles Shore Fellowship by Harvard Medical School and is a current recipient of a 372 NephCure/NEPTUNE ancillary study award. G.L. is supported by NIH grant DK007053-45S1. 373 A.G. is supported by NIH grants DK099465 and DK095045. S.W. is supported by NIH grants 374 U01DK085660, U01DK104308, and UG3DK114915. M.S. is supported by NIH grant 375 R01DK119380 and R01DK1088085. A.G. has financial interest in Goldfinch Biopharma, which 376 was reviewed and is managed by Brigham and Women's Hospital, Mass General Brigham, the 377 Broad Institute and Harvard University in accordance with their conflict of interest policies. 378 A.J.B.W., K.H.K., A.W., J.M.H and H.G.R. have filed a provisional patent "Methods for 379 identifying and treating patients with antibody-mediated acquired primary or recurrent idiopathic 380 nephrotic syndrome". The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-381 DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research 382 Network (RDCRN), supported through a collaboration between the Office of Rare Diseases 383 Research (ORDR), NCATS, and the National Institute of Diabetes, Digestive, and Kidney 384 Diseases. Additional funding and/or programmatic support for this project has also been 385 provided by the University of Michigan, the NephCure Kidney International and the Halpin 386 Foundation.

387

388 **References**

- Vivarelli, M., Massella, L., Ruggiero, B. & Emma, F. Minimal Change Disease. *Clin J Am Soc Nephrol* 12, 332-345 (2017).
- 391 2. Grahammer, F., Schell, C. & Huber, T.B. The podocyte slit diaphragm--from a thin grey
 392 line to a complex signalling hub. *Nat Rev Nephrol* 9, 587-598 (2013).
- 393 3. Khoshnoodi, J., *et al.* Nephrin promotes cell-cell adhesion through homophilic
 394 interactions. *Am J Pathol* 163, 2337-2346 (2003).
- Kestila, M., *et al.* Positionally cloned gene for a novel glomerular protein--nephrin--is
 mutated in congenital nephrotic syndrome. *Mol Cell* 1, 575-582 (1998).
- Liu, L., *et al.* Defective nephrin trafficking caused by missense mutations in the NPHS1
 gene: insight into the mechanisms of congenital nephrotic syndrome. *Hum Mol Genet* 10, 2637-2644 (2001).
- 400 6. Elie, V., Fakhoury, M., Deschenes, G. & Jacqz-Aigrain, E. Physiopathology of idiopathic
 401 nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. *Pediatr*402 *Nephrol* 27, 1249-1256 (2012).
- 403 7. Coward, R.J., *et al.* Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes.
 405 J Am Soc Nephrol 16, 629-637 (2005).
- 8. Ravani, P., Bertelli, E., Gill, S. & Ghiggeri, G.M. Clinical trials in minimal change disease. *Nephrol Dial Transplant* 32, i7-i13 (2017).
- 408 9. Ravani, P., Bonanni, A., Rossi, R., Caridi, G. & Ghiggeri, G.M. Anti-CD20 Antibodies
 409 for Idiopathic Nephrotic Syndrome in Children. *Clin J Am Soc Nephrol* 11, 710-720
 410 (2016).
- 411 10. Basu, B., *et al.* Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid412 Dependent Nephrotic Syndrome: A Randomized Clinical Trial. *JAMA Pediatr* 172, 757413 764 (2018).
- 414 11. Basu, B. Ofatumumab for rituximab-resistant nephrotic syndrome. *N Engl J Med* 370, 1268-1270 (2014).
- 416 12. Fenoglio, R., *et al.* Rituximab as a front-line therapy for adult-onset minimal change
 417 disease with nephrotic syndrome. *Oncotarget* 9, 28799-28804 (2018).
- 418 13. Madanchi, N., Bitzan, M. & Takano, T. Rituximab in Minimal Change Disease:
 419 Mechanisms of Action and Hypotheses for Future Studies. *Can J Kidney Health Dis* 4, 2054358117698667 (2017).
- 421 14. D'Agati, V.D. Minimal Change Disease. in *Atlas of Nontumor Pathology. Non-neoplastic*422 *Kidney Kidney Diseases.*, Vol. Fascicle 4 109 (American Registry of Pathology,
 423 Washington, DC, 2005).
- 424 15. Orikasa, M., Matsui, K., Oite, T. & Shimizu, F. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. *J Immunol* 141, 807-814 (1988).
- Topham, P.S., *et al.* Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. *J Clin Invest* 104, 1559-1566 (1999).
- Takeuchi, K., *et al.* New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using
 a C57BL/6 Mouse Strain. *Nephron* 138, 71-87 (2018).
- Holmberg, C. & Jalanko, H. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. *Pediatr Nephrol* 29, 2309-2317 (2014).

- 432 19. Kuusniemi, A.M., *et al.* Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1).
 434 *Transplantation* 83, 1316-1323 (2007).
- 435 20. Doublier, S., *et al.* Nephrin redistribution on podocytes is a potential mechanism for
 436 proteinuria in patients with primary acquired nephrotic syndrome. *Am J Pathol* 158,
 437 1723-1731 (2001).
- 438 21. Wernerson, A., *et al.* Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome. *Nephrol Dial Transplant* 18, 70-76 (2003).
- 440 22. Hammers, C.M. & Stanley, J.R. Mechanisms of Disease: Pemphigus and Bullous
 441 Pemphigoid. *Annu Rev Pathol* 11, 175-197 (2016).
- Gadegbeku, C.A., *et al.* Design of the Nephrotic Syndrome Study Network (NEPTUNE)
 to evaluate primary glomerular nephropathy by a multidisciplinary approach. *Kidney Int*83, 749-756 (2013).
- 445 24. Gustafsson, M.G. Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy. *J Microsc* 198, 82-87 (2000).
- 447 25. Nguyen, V.T., *et al.* Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal
 448 effects on keratinocytes. *J Biol Chem* 279, 2135-2146 (2004).
- 449 26. Xing, C.Y., *et al.* Direct effects of dexamethasone on human podocytes. *Kidney Int* 70, 1038-1045 (2006).
- 451 27. Jun, G., Wing, M.K., Abecasis, G.R. & Kang, H.M. An efficient and scalable analysis
 452 framework for variant extraction and refinement from population-scale DNA sequence
 453 data. *Genome Res* 25, 918-925 (2015).
- 454 28. Gillies, C.E., *et al.* An eQTL Landscape of Kidney Tissue in Human Nephrotic 455 Syndrome. *Am J Hum Genet* **103**, 232-244 (2018).
- 456 29. Sampson, M.G., *et al.* Using Population Genetics to Interrogate the Monogenic Nephrotic
 457 Syndrome Diagnosis in a Case Cohort. *J Am Soc Nephrol* 27, 1970-1983 (2016).
- 30. Richards, S., *et al.* Standards and guidelines for the interpretation of sequence variants: a
 joint consensus recommendation of the American College of Medical Genetics and
 Genomics and the Association for Molecular Pathology. *Genet Med* 17, 405-424 (2015).
- 461 31. Beck, L.H., Jr., *et al.* M-type phospholipase A2 receptor as target antigen in idiopathic
 462 membranous nephropathy. *N Engl J Med* 361, 11-21 (2009).
- 463 32. Hiraoka, Y., Sedat, J.W. & Agard, D.A. Determination of three-dimensional imaging
 464 properties of a light microscope system. Partial confocal behavior in epifluorescence
 465 microscopy. *Biophys J* 57, 325-333 (1990).
- 466 33. Matsuda, A., Schermelleh, L., Hirano, Y., Haraguchi, T. & Hiraoka, Y. Accurate and
 467 fiducial-marker-free correction for three-dimensional chromatic shift in biological
 468 fluorescence microscopy. *Sci Rep* 8, 7583 (2018).





Figure 1: Circulating autoantibodies against nephrin are present in a subset of MCD patients from the NEPTUNE study cohort and correlate with disease activity.

(a) Antibodies against the extracellular domain of recombinant human nephrin (hNephrin_{G1059}) were measured by indirect ELISA. Antigen specific binding was determined by subtracting the average OD_{450nm} of duplicate uncoated wells (nonspecific background) from the average OD_{450nm} of duplicate hNephrin_{G1059} coated wells for each individual patient sample. A relative antibody titer was then determined from a standard curve that was generated using a single positive patient sample with a 1:100 dilution defined as containing 1000 Units/ml. The threshold for anti-nephrin antibody positivity (187 Units/ml) was defined as the maximum antibody titer, as the cohort was not normally distributed, in a healthy control population (n=30) with no known kidney disease (dotted line) to maximize specificity. The earliest serum sample available during active disease (urine protein creatinine ratio (UPCR) > 3 g/g on the day of sample collection) was positive for anti-nephrin antibodies in 18 (29%) of 62 patients with biopsy proven MCD from the NEPTUNE cohort. 53 (98%) of 54 nephrotic control patients with anti-human phospholipase A_2 receptor (hPLA₂R+) antibodies, as determined by clinical ELISA and IIFT assays (Euroimmun), were negative for anti-nephrin antibodies. The intra and inter-assay coefficient of variances for the antinephrin antibody ELISA were 5.56% and 14.36% respectively. The antibody titer for the NEPTUNE patients and controls are given in Supplemental Table S1. (b) 11 of the 18 NEPTUNE patients who were anti-nephrin antibody positive during active disease (blue bar) had a subsequent serum sample available during complete remission (UPCR < 0.3 g/g on the day of sample collection) which tested anti-nephrin antibody negative (red bar) in all cases. Dotted line indicates threshold for positive antibody titer (187 Units/ml). Student t-test was used to compare differences between the active and remission samples **p<0.01, ***p<0.001. (c) The same serum samples

evaluated by ELISA from the NEPTUNE cohort (b) were evaluated for their ability to immunoprecipitate nephrin from HGE (derived from non-diseased human kidney). In keeping with the ELISA results, only serum obtained during active disease (indicated by an arrow with an A (blue colored) above it) immunoprecipitated nephrin, whereas serum obtained during remission (indicated by an arrow with a R (red colored) above it) did not. Total IgG was comparable between active and remission samples for each patient.



Figure 2

Figure 2: Renal biopsy imaging studies and serological testing for anti-nephrin antibodies in patients with biopsy proven MCD

(a) Representative confocal microscopy images of glomeruli in IgG-positive MCD (MCD1+/MCD7+) and IgG-negative MCD (MCD5-), stained for IgG (green) and the podocyte slit-diaphragm protein nephrin (red). There is a clear overlap (yellow) between IgG (green) and nephrin (red) specifically with the punctate IgG and not background as seen in the MCD+ biopsies (MCD1+/MCD7+) (white arrows) but not in MCD- biopsies. The right panels show magnified images of boxed areas of MCD1+ and MCD7+ biopsies. Scale bar: 10µm. (b) Representative confocal microscopy images of glomeruli in IgG-positive MCD (MCD1+/MCD7+) and IgGnegative MCD (MCD5-), stained for punctate IgG (green) (indicated with white arrow) and the cytoskeletal podocyte marker synaptopodin (red). There is no appreciable overlap between IgG and Synaptopodin in any of those cases. The right panels show magnified images of boxed areas of MCD1+ and MCD7+ biopsies. Scale bar: 10µm. (c) Super Resolution Structured Illumination Microscopy (SIM) images of 0.125 µm individual Z-slices showing en face views of the podocyte junction from a representative renal biopsy (MCD1+) in which the nephrin remains GBMassociated, forming a curvilinear pattern. The left image shows co-localization (yellow) of IgG (green) with the slit diaphragm protein nephrin (red), in contrast to mutual exclusivity with the foot process associated synaptopodin (red) shown in the right image, indicating intimate spatial association with nephrin along the podocyte slit diaphragm. (Full image stack shown in Figure S8). Scale bar: 1 μm. (d) SIM image of 0.125 μm individual Z-slices from a representative renal biopsy (patient MCD7+) in which nephrin is redistributed to a more granular pattern. The left image shows co-localization (yellow) of IgG (green) with the slit diaphragm protein nephrin (red), in contrast to mutual exclusivity with the foot process associated synaptopodin (red) shown in the

right image, indicating a continued close spatial association of the IgG with the redistributed nephrin. (Full image stack shown in supplemental Figure S8). Scale bar: 1 µm. (e) All of the patients with MCD and IgG deposition on biopsy (n=9) were anti-nephrin antibody positive, whereas all of the control subjects lacking IgG deposition on biopsy, consisting of DN (n=2), Amyloidosis (n=1), IgG-negative FSGS (n=2), IgG-negative TL (n=1), normal (n=1), disease-free region of tumor nephrectomy (n=2) and IgG-negative MCD (n=3), were anti-nephrin antibody negative (n=12). The Mann-Whitney U test was used to compare differences between the groups ***p<0.001. (f) Serum/plasma samples were obtained from patients with biopsy proven IgGpositive MCD (MCD+) during active disease (within 7 days of presentation with NS) and followup samples were obtained during complete (MCD4+, MCD7+) or partial (MCD8+) remission on the day of sample collection. For MCD3+, the follow-up serum sample was obtained approximately 3 weeks after entering a period of sustained complete remission. The threshold for a positive anti-nephrin antibody titer of 187 U/ml (indicated by dotted line) was based on the upper limit of a healthy control population. Anti-nephrin antibodies in serum/plasma were undetectable or significantly reduced to below the threshold for positivity, (red bar) during clinical remission compared with those during active disease (blue bar). Complete remission was defined as urinary protein creatinine ratio (UPCR) < 0.3 g/g or urinary albumin creatinine ratio (UACR) < 0.2 g/g. Partial remission was defined as a > 50% reduction in proteinuria (UPCR) that did not fall below 0.3 g/g. Student t-test was used to compare differences between the active and remission samples **p<0.01, ***p<0.001.